Literature DB >> 20188594

Deposition of C4d and C3d in cardiac transplants: a factor in the development of coronary artery vasculopathy.

Ellen L Moseley1, Carl Atkinson, Linda D Sharples, John Wallwork, Martin J Goddard.   

Abstract

BACKGROUND: Coronary artery vasculopathy (CAV) is the major life-limiting factor in cardiac transplantation, after 1 year. Antibody-mediated rejection (AMR) has been associated with development of both acute and chronic rejection. We analyzed endomyocardial biopsies for pathologic markers of AMR (C4d and C3d), from the first 2 years post-transplantation, to determine complement deposition in relation to the development of CAV.
METHODS: A retrospective, matched-pair study was used. Group 1 subjects (n = 26) were CAV-negative at 8 years, and Group 2 (n = 26) had angiographically detectable CAV at 4 years. Biopsies from six time-points were studied (total = 282). Immunohistochemistry was performed for C4d, C3d and CD68. Biopsies were graded for rejection using ISHLT criteria.
RESULTS: Although CAV was not significantly associated with C4d deposition, it was associated with C3d deposition (p = 0.043). Only 4% of C4d and 5% of C3d biopsies were completely negative. Group 1 had 6 AMR-positive biopsies, with Group 2 having 8. There was no significant relationship between acute cellular rejection or AMR events and CAV.
CONCLUSIONS: This study demonstrates that complement deposition is a frequent occurrence in the first 2 years post-transplantation. Although acute rejection is a known risk factor for CAV, in this study the relationship was found not to be significant. No relationship was found with the development of CAV and histologic features of AMR, when assessed by C4d deposition alone. However, an association between C3d deposition and the development of CAV was determined in this study group, suggesting that complement activation may play a role in the pathogenesis of CAV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188594     DOI: 10.1016/j.healun.2009.12.018

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

1.  Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.

Authors:  Peng Zhu; Stefanie R Bailey; Biao Lei; Chrystal M Paulos; Carl Atkinson; Stephen Tomlinson
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

Review 2.  Heart transplantation research in the next decade--a goal to achieving evidence-based outcomes: National Heart, Lung, And Blood Institute Working Group.

Authors:  Monica R Shah; Randall C Starling; Lisa Schwartz Longacre; Mandeep R Mehra
Journal:  J Am Coll Cardiol       Date:  2012-04-03       Impact factor: 24.094

3.  Report from a consensus conference on antibody-mediated rejection in heart transplantation.

Authors:  Jon Kobashigawa; Maria G Crespo-Leiro; Stephan M Ensminger; Hermann Reichenspurner; Annalisa Angelini; Gerald Berry; Margaret Burke; Lawrence Czer; Nicola Hiemann; Abdallah G Kfoury; Donna Mancini; Paul Mohacsi; Jignesh Patel; Naveen Pereira; Jeffrey L Platt; Elaine F Reed; Nancy Reinsmoen; E Rene Rodriguez; Marlene L Rose; Stuart D Russell; Randy Starling; Nicole Suciu-Foca; Jose Tallaj; David O Taylor; Adrian Van Bakel; Lori West; Adriana Zeevi; Andreas Zuckermann
Journal:  J Heart Lung Transplant       Date:  2011-03       Impact factor: 10.247

4.  Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts.

Authors:  Carl Atkinson; Bernhard Floerchinger; Fei Qiao; Sarah Casey; Tucker Williamson; Ellen Moseley; Serban Stoica; Martin Goddard; Xupeng Ge; Stefan G Tullius; Stephen Tomlinson
Journal:  Circulation       Date:  2013-02-26       Impact factor: 29.690

5.  Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy.

Authors:  Keely M Marshall; Songqing He; Zhi Zhong; Carl Atkinson; Stephen Tomlinson
Journal:  J Exp Med       Date:  2014-08-11       Impact factor: 14.307

Review 6.  Cardiac allograft vasculopathy: current review and future research directions.

Authors:  Jordan S Pober; Sharon Chih; Jon Kobashigawa; Joren C Madsen; George Tellides
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

7.  Coincidence of cellular and antibody mediated rejection in heart transplant recipients - preliminary report.

Authors:  Michał Zakliczyński; Jerzy Nożyński; Dominika Konecka-Mrówka; Agnieszka Babińska; Bożena Flak; Tomasz Hrapkowicz; Marian Zembala
Journal:  Kardiochir Torakochirurgia Pol       Date:  2014-03-27

8.  Noninvasive and quantitative measurement of C4d deposition for the diagnosis of antibody-mediated cardiac allograft rejection.

Authors:  Tao Liao; Xiaonan Liu; Jie Ren; Hongjun Zhang; Haofeng Zheng; Xiujie Li; Yannan Zhang; Fei Han; Tinghui Yin; Qiquan Sun
Journal:  EBioMedicine       Date:  2018-10-29       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.